437 related articles for article (PubMed ID: 21854080)
1. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
[TBL] [Abstract][Full Text] [Related]
2. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
4. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.
Yang H; Craig D; Epstein D; Bojke L; Light K; Bruce IN; Sculpher M; Woolacott N
Pharmacoeconomics; 2012 Apr; 30(4):257-70. PubMed ID: 22283690
[TBL] [Abstract][Full Text] [Related]
5. Denosumab for the prevention of osteoporotic fractures in postmenopausal women.
Waugh N; Royle P; Scotland G; Henderson R; Hollick R; McNamee P
Health Technol Assess; 2011 May; 15 Suppl 1():51-9. PubMed ID: 21609653
[TBL] [Abstract][Full Text] [Related]
6. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
Stevenson M; Davis S; Lloyd-Jones M; Beverley C
Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
Hiligsmann M; Reginster JY
Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
[TBL] [Abstract][Full Text] [Related]
9. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.
Kilonzo M; Hislop J; Elders A; Fraser C; Bissett D; McClinton S; Mowatt G; Vale L
Pharmacoeconomics; 2013 Jan; 31(1):15-24. PubMed ID: 23329590
[TBL] [Abstract][Full Text] [Related]
10. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
11. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.
Rodgers M; Griffin S; Paulden M; Slack R; Duffy S; Ingram JR; Woolacott N; Sculpher M
Pharmacoeconomics; 2010; 28(5):351-62. PubMed ID: 20131924
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
13. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
You R; Mori T; Ke L; Wan Y; Zhang Y; Luo F; Feng D; Yu G; Liu J
Menopause; 2021 Dec; 29(2):210-218. PubMed ID: 34930866
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.
Boyers D; Jia X; Jenkinson D; Mowatt G
Pharmacoeconomics; 2012 Jun; 30(6):483-95. PubMed ID: 22480381
[TBL] [Abstract][Full Text] [Related]
15. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.
McKenna C; Maund E; Sarowar M; Fox D; Stevenson M; Pepper C; Woolacott N; Palmer S
Pharmacoeconomics; 2012 Jan; 30(1):35-46. PubMed ID: 22136303
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan.
Mori T; Crandall CJ; Fujii T; Ganz DA
Arch Osteoporos; 2021 Jul; 16(1):113. PubMed ID: 34264429
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Davis S; Martyn-St James M; Sanderson J; Stevens J; Goka E; Rawdin A; Sadler S; Wong R; Campbell F; Stevenson M; Strong M; Selby P; Gittoes N
Health Technol Assess; 2016 Oct; 20(78):1-406. PubMed ID: 27801641
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Denosumab for Secondary Prevention of Osteoporotic Fractures Among Postmenopausal Women in China: An Individual-Level Simulation Analysis.
Jiang Y; Jiang S; Li L; Shi S; Li M; Si L
Appl Health Econ Health Policy; 2023 May; 21(3):489-499. PubMed ID: 36626041
[TBL] [Abstract][Full Text] [Related]
19. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]